Table of Contents Table of Contents
Previous Page  56 / 114 Next Page
Information
Show Menu
Previous Page 56 / 114 Next Page
Page Background

52

NCCN Guidelines for Patients

®

Breast Cancer - Early-Stage

(STAGES I AND II)

, Version 1.2016

Regimens: HER2-positive cancer

4

Chemotherapy and HER2 inhibitors Regimens: HER-2 positive cancer

*Preferred and other regimens are based on how well they work, side effects, and treatment schedules.

Chart 4.6 Preferred regimens*

Preferred Regimen

Schedule

Total time

AC

Four 21-day cycles

1 year and 3 months

then paclitaxel

Twelve 7-day cycles

with trastuzumab

Weekly during paclitaxel then every 7 or 21 days

to complete 1 year

AC

Four 21-day cycles

1 year and 3 months

then paclitaxel

Four 21-day cycles

with pertuzumab

Weekly during paclitaxel

and trastuzumab

Weekly during paclitaxel then every 21 days to

complete 1 year

Dose-dense AC

Four 14-day cycles

1 year and 2 months

then paclitaxel

Four 14-day cycles

with trastuzumab

Weekly during paclitaxel then every 7 to 21 days

to complete 1 year

TCH

Six 21-day cycles with weekly trastuzumab, then

trastuzumab every 21 days to complete 1 year

1 year

TCH + pertuzumab

Six 21-day cycles with weekly trastuzumab and

pertuzumab then trastuzumab every 21 days to

complete 1 year

1 year

Abbreviations

:

AC = doxorubicin + cyclophosphamide; FEC = fluorouracil + epirubicin +

cyclophosphamide; TCH = docetaxel + carboplatin + trastuzumab

Chart 4.7 Other regimens*

Other Regimen

Schedule

Total time

AC

Four 21-day cycles

1 year and 3 months

then docetaxel

Four 21-day cycles

with trastuzumab

Weekly during docetaxel cycles then every

21 days to complete 1 year

Continues on next page.